Molecular Diagnostics
British Journal of Cancer (2009) 101, 295–302. doi:10.1038/sj.bjc.6605138 www.bjcancer.com
Published online 23 June 2009
Identification of macrophage migration inhibitory factor and human neutrophil peptides 1–3 as potential biomarkers for gastric cancer
Y Mohri1,2, T Mohri1,3, W Wei1, Y-J Qi1, A Martin1, C Miki4, M Kusunoki4, D G Ward1 and P J Johnson1
- 1Cancer Research UK, Institute for Cancer Studies, School of Cancer Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK
- 2Department of Innovative Surgery, Graduate School of Medicine, Mie University, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan
- 3Department of Surgery, Toyama Hospital, 17-22, Minami-Schinmachi, Tsu, Mie, 514-0043, Japan
- 4Department of Gastrointestinal and Pediatric Surgery, Graduate School of Medicine, Mie University, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan
Correspondence: Professor PJ Johnson, E-mail p.johnson@bham.ac.uk
Received 12 February 2009; Revised 18 May 2009; Accepted 21 May 2009; Published online 23 June 2009.
Abstract
Background:
Proteomic methods have the potential to meet the urgent need for better cancer biomarkers. We have used a range of proteomic analyses of serum and tissue from gastric cancer patients and relevant controls to discover biomarkers for gastric cancer.
Methods:
Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI) and antibody arrays were used to compare protein expression in 21 pairs of gastric cancer tissue and adjacent normal mucosa and serum from 51 gastric cancer patients and 29 patients with benign gastric diseases. Expression differences were confirmed by enzyme-linked immunosorbent assay.
Results:
Tissue analysis shows human neutrophil peptides 1–3 (HNPs 1–3) elevated 10-fold (P=0.001) in gastric cancer relative to adjacent normal mucosa. Macrophage migration inhibitory factor (MIF) was increased five-fold (P=1.84 
10-7) in the serum of gastric cancer patients relative to individuals with benign gastric disease. The large increase in MIF concentration in serum gives an area under the receiver operating characteristic curve of 0.85.
Conclusions:
Proteomic analyses of serum and tissue indicate that HNPs 1–3 and MIF have potential as biomarkers for gastric cancer. In particular MIF may be useful, either alone or in combination with other markers, for diagnosing and monitoring gastric cancer.
Keywords:
gastric, biomarker, serum, proteome
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Technology Insight: the application of proteomics in gastrointestinal disease
Nature Clinical Practice Gastroenterology & Hepatology Review (01 Jul 2007)
Technology Insight: the application of proteomics in gastrointestinal disease
Nature Clinical Practice Gastroenterology & Hepatology Review (01 Jul 2007)
Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers
Nature Clinical Practice Gastroenterology & Hepatology Review (01 Mar 2009)
Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers
Nature Clinical Practice Gastroenterology & Hepatology Review (01 Mar 2009)
RESEARCH
Identification of serum biomarkers for colon cancer by proteomic analysis
British Journal of Cancer Original Article
